nature jobs.com - the premier science recruitment website

NPG's BioPartnering is dedicated to small and large companies looking for commercial partnerships and finding out more about licensing. Find executive profiles from companies actively looking for partners.

BioPharma Dealmakers

Merck's pending merger with Schering-Plough should provide more resources for more collaborations at all stages. With the integration process underway, it's "Business as Usual" for Merck's licensing program—a continued focus on pursuing partnerships of all types.

Crucell N.V. has developed a range of platform technologies to speed up and ease the development of vaccines and proteins (including antibodies). In addition to using its platform technologies for in-house vaccine and therapeutic development, Crucell is providing partners and licensees with access to these technologies and processes, including its highyielding human cell line technology PER.C6®.

GSK increases its hunt for early stage biotech companies. We are looking for innovation wherever it may originate. Learn more on www.ceedd.com.


Teva Pharmaceutical Industries Ltd is probably better known as one of the largest generic pharmaceutical companies in the world but it does have a growing interest in in-licensing medicines that can be used by specialist clinicians from both biotech and academic sources. Historically, it has sourced its innovative assets from within Israel but it is now looking to access innovative, pre-clinical programs from U.S. and European sources.

Biological drug development is an expensive process, and companies developing therapeutics look to save money at every stage. However, according to SynCo Bio Partners, investing in planning process development early in the drug development cycle could save money and time at a later stage, and could even mean the difference between marketing approval and rejection.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is seeking partners who will share the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world.

We are not only at the forefront of conquering newly targeted diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

Formed as a spin-out company from Grupo Uriach's research and development unit in November 2006, Palau Pharma S.A. focuses on the development of innovative small molecule therapeutics from discovery to clinical proof-of-concept for the treatment of inflammatory and autoimmune diseases in areas of unmet medical need.

HUNT Biosciences is the commercial arm of the HUNT Databank, one of the world's most comprehensive population-based prospective health surveys and biobanks.

DBV Technologies (DBV) is a company focused on non-invasive epicutaneous drug delivery. Its patented technology platform VIASKIN® uses electrostatic forces to deliver compounds non-invasively to the epidermis without disrupting the blood-skin barrier. VIASKIN®; has a broad applicability across allergy diagnostics, specific immunotherapy, vaccine delivery and cosmaceuticals. DBV is currently seeking partners in these areas.

Novo Nordisk seeks partners to increase its promising, protein-based pipeline within diabetes, haemostasis and chronic inflammation. Novo Nordisk masters all aspects of bringing proteins from molecule to market, and employs more than 25,000 staff in 79 countries worldwide.

 
 

The Health Protection Agency's core business areas are research and development of vaccines against infectious diseases, process development and GMP manufacture of biologics. In addition, a wide range of support services are offered from biosafety, through GLP immunoassay testing to in vivo studies.

BTG in-licenses, develops and commercialises pharmaceuticals. Principally in the field of neuroscience but also in other areas. The company has a substantial and growing revenue stream of royalties from out licensed products and a broad, expanding internal pipeline of development programmes. This company is evolving towards growing a later stage pipeline, eventually aiming to take niche products to market. This will be funded by milestones and royalties from partnered programs, including two projects in Phase III and seven in Phase II.

Institut Pasteur acknowledges that the best performers in the Pharma Industry have shifted from focused collaborations with academia to more widely open research programs with centers of excellence.

We have gathered a special purpose team to define with each company the research collaborations needed to find solutions to knowledge deadlocks in product development programs.

Antisense Pharma focuses on the development of gene silencing therapies against highly malignant cancers. We identify and develop antisense drugs, which specifically down-regulate key cancer mediating proteins. Our lead compound AP 12009 is in advanced clinical development stage for high-grade glioma (Phase IIb completed) and other solid tumors and is available for worldwide partnering.

Open for Business - Imperial offers unique opportunities to enhance innovation in R&D through collaborative research, technology licensing and consulting - current partners include major healthcare, biotech and pharmaceutical companies in a wide range of deal-structures. Deal-making support is provided by the BioPharma Business Development team led by Dominique Kleyn.

UCL Business is the access point to the wealth of innovation and intellectual property emanating from UCL, and we offer a number of services to assist the technology transfer process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Affitech discovers and develops fully human antibody therapeutics for both partners, such as Roche and Peregrine, and its own pipeline with a primary focus in oncology. Headquartered in Oslo, Norway with business development in San Francisco, California, Affitech uses two proprietary discovery technologies - MBAS (molecule based) and CBAS(cell based). By discovering both antibody and target simultaneously from patient libraries CBAS shortens development times by up to two years.

Q-Chip's proprietary MicroPlant system for biological packaging and stabilisation, best imagined as Tetra Pak on a very small scale, is available to license for multiple applications in molecular diagnostics and pharmaceutical markets.

P&G Pharmaceuticals offers potential partners the best of both worlds: the unique insights and marketing expertise of the world's largest consumer products company and also the personal touch of a focused pharmaceutical company that's small enough to give each development project and marketed product the attention it deserves.

Sidec offers collaborative research to better select, protect and market therapeutic antibodies and other biotherapeutics. Clients are big pharma as well as biotechnology companies. Sidec AB is a rapidly growing, Swedish company providing collaborative research based on its proprietary technology, Protein Tomography™, and expertise in characterization of biologicals. Protein Tomography™ studies add unique value in biological candidate discovery, for IP protection and in marketing.

Debiopharm is a financially independent drug development company based in Lausanne, Switzerland, that in-licenses promising therapeutic compounds, develops them globally and then out-licenses them for commercialization. By concentrating only on the development of products rather than on external investors and sales and marketing, Debiopharm has become a highly successful developer.

VIA Pharmaceuticals, Inc. is a biotechnology company located in San Francisco, California, which is focused on the development of therapeutics for the treatment of cardiovascular disease. Its lead compound, VIA-2291, is currently in Phase II clinical trials in North America and Europe. It targets inflammation in the blood vessel, the underlying cause of cardiovascular disease.

  • Advertising Profiles
    For more information about BioPharma Dealmakers or to purchase an Advertising Profile please contact:
    Graham Combe
    Business Development, BioPharma
    Email: g.combe@nature.com
    Telephone: +44 (0)20 7843 4914

Partnering Features

Pharma's Predicament is Biotech's Bonanza
Patent expirations are on the verge of creating giant gaps in pharma revenue streams, and in this feature from May '09 BioPharma Dealmakers, writer George Mack believes the mega-merger approach is only a temporary solution. A new approach is needed, let the new era for biotech begin in earnest.

Download Article

 

 

The Right Stuff
Despite global economic woes, the biopharmaceutical industry's intrinsic value continues to build. In the October'08 edition of BioPharma Dealmakers, freelance journalist Crispin Littlehales looks into the latest strategies of the most prolific dealmakers in the biopharma industry? A range of different organizations, from universities to biotech and pharma companies, provide their views on the global partnering outlook.

Download Article

 

 

No Guts No Glory
When the going get's tough, the tough get going! In this article from the June'08 Licensing Executive Profiles, freelance journalist Crispin Littlehales interviews some of the industry's leading Dealmakers. Through this we see some of the most courageous partnering strategies from the major players, giving insight into how the marketplace is shaping up.

Download Article

 

 

Let's make a Deal
In this article from the October'07 Licensing Executive Profiles, freelance journalist Crispin Littlehales analyzes the global biopartnering marketplace. Here you can glean insight from some of the most prolific biopartnering deal makers, who indicate what it is the major pharmaceutical and biotech companies are looking for from potential biotech collaborators.

Download Article

 

 

ADVERTISEMENT